A study of aspirin resistance in type 2 diabetes

Journal of the Indian Medical Association

Volumn 106, Issue 11, 2008, Pages

  Singla, Mani Kant ^a   Lahiri, Prabir ^a,b   Mukhopadhyay, Pradip ^a   Pandit, Kaushik ^a   Chaudhuri, Utpal ^a,b   Chowdhury, Subhankar ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Aspirin resistance; Coronary artery disease; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL; ANTITHROMBOCYTIC AGENT;

ADULT; AMINO ACID URINE LEVEL; ARTERY DISEASE; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG SENSITIVITY; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; SMOKING; STROKE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD CLOTTING PARAMETERS; DIABETIC ANGIOPATHY; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; RISK FACTOR; THROMBOCYTE AGGREGATION;

ASPIRIN; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG RESISTANCE; HUMANS; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RISK FACTORS; TRIGLYCERIDES;

EID: 65449156011     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Nicolucci A, De Berardis G, Sacco M, Tognoni G - AHA/ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 2007; 28: 1925-1927
2. Ajjan R, Storey RF, Grant PJ - Aspirin resistance and diabetes mellitus. Diabetologia 2008; 51: 385-390
3. Antithrombotic Trialists' Collaboration - Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86. (Pubitemid 34073138)
4. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A - PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264-3272
5. Sanderson S, Emery J, Baglin T, Kinmonth AL - Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142: 370-380 (Pubitemid 40293410)
6. Lahiri P, Chaudhuri U, Dasgupta AK, Ray SN, Saha S, Mukherjee P - Insensitivity to the a2-adrenergic receptor blocker yohimbine hydrochloride and occurrence of spontaneous platelet macroaggregation (SPMA) in diabetes. Platelets 2005; 16: 111-115 (Pubitemid 40516676)
7. Watala C, Pluta J, Golanski J - Increased protein glycation in diabetes mellitus is associated with decreased aspirinmediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005; 83: 148-158 (Pubitemid 40379303)
8. Hung J, Lam JY, Lacoste L, Letchacovski G - Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-2436
9. Tantry US, Bliden K, Gurbel P - Overestimation of aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. JAm Coll Cardiol 2005; 46: 1705-9. (Pubitemid 41531626)
10. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al - Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235 (Pubitemid 32721947)
11. Rao GH, Johnson GG, Reddy KR, White JG. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983; 3: 383-388
12. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortarice KL, et al - Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-2336 (Pubitemid 24359298)
13. Halushka MK, Halushka PV - Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002; 105: 1620-1622
14. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H - Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63-66 (Pubitemid 36206686)
15. McKee SA, Sane DC, Deliargyris EN - Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88: 711-715
16. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC - Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 2008; 6: 46.
17. Fateh-Moghadam S, Plockinger U, Cabeza N - Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005; 42: 99-103. (Pubitemid 40881115)
18. Eikelboom JW, Hirsh J, Wetiz JI, Johnston M, Yi Q, Yusuf S - Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655 (Pubitemid 34298607)